Partnership Formed to Offer Next Generation Technologies and Services for Better Drug Cardiac Safety

Washington, DC – January 12, 2009 – At CBI’s 3rd Annual Cardiac Safety Summit, Spaulding Clinical and OBS Medical announced that they have entered into a strategic relationship to promote an integrated suite of technologies and services for improving cardiac safety.

The non-exclusive partnership between OBS Medical and Spaulding Clinical will provide comprehensive cardiac safety services including patient recruitment, ECG/Holter data collection, in-depth cardiac safety analysis (high-throughput with cardiologist involvement), and expert cardiologist interpretation and summary.  This joint offering is positioned to be the industry’s premier cardiac safety service, as measured by data quality, breadth and depth of analysis, project completion time, and cost efficiency.

Spaulding Clinical is a Phase I clinical trial facility with comprehensive and leading-edge services.  With the most advanced technology, its integration of monitoring, recording, analyzing and reporting are all in one place. A unique specialization in cardiac safety testing for new drugs in development, Spaulding Clinical provides the highest quality results with the most accurate data and the most efficient procedures in the industry.

“We are delighted to select OBS Medical’s BioQT™ cardiac safety analytical platform for inclusion into our comprehensive Phase I services,” commented Randy Spaulding, Spaulding Clinical CEO.  “BioQT is built upon a strong scientific foundation, clinically validated with strong results and positioned to assist more pharmaceutical sponsors in their drugs’ cardiac safety analysis.  Spaulding Clinical is excited to enter into this partnership with OBS Medical so together we can offer the best cardiac safety services.”

OBS Medical provides innovative clinical algorithms such as BioQT, an advanced signal processing technique.  BioQT generates an efficient and accurate measurement of ECG QT interval, T wave morphology and other cardiac safety parameters assessed during drug trials.  It is a thorough and efficient way to produce accurate cardiac safety profiles for new and existing drugs.  OBS Medical recently conducted an industry-first cardiac safety study in which BioQT high-throughput analytical platform was used to prospectively analyze QT and T wave morphology changes for a drug compound.  BioQT data was among the information used by the FDA to allow the drug to move into its next phase of development.

“OBS Medical is thrilled about our partnership with Spaulding Clinical – together we will offer next generation technologies and services for improving cardiac safety,” commented Frank Cheng, OBS Medical CEO.  “Spaulding Clinical’s facilities are state-of-the-art, and its commitment to the highest service quality and standards and passionate pursuit of ingenious solutions will save time and money for pharmaceutical clients.”

 

About Spaulding Clinical

Spaulding Clinical is a 48 telemetry bed facility in West Bend, WI specializing in cardiac safety testing.  Spaulding Clinical offers a range of services including first-in-human studies, bioavailability and bioequivalence, data collection and management, definitive QTc, and Pharmacokinetics and Pharmacodynamics. Spaulding Clinical also offers ECG Core Lab and Over-reading services with state-of-the-art technology and cardiac expertise.

Contact:

Spaulding Clinical
Amanda Baltz
262.306.3324
amanda.baltz@spauldingclinical.com

Spaulding Clinical
525 S. Silverbrook Drive
West Bend, WI 53095
USA
www.spauldingclinical.com

 

About OBS Medical

OBS Medical is based in Carmel, Indiana and provides innovative clinical algorithms for safer hospitals, safer patients and safer drugs.  Based on intelligent algorithms such as neural networks, data fusion and ECG waveform recognition, OBS Medical technologies cover a range of medical applications including automated early crisis warning (Visensia®), automated assessment of ECG waveforms including QT interval measurement and morphology tracking (BioQT™), and EEG analysis for brain-state assessment.  OBS Medical is a wholly-owned subsidiary of Oxford BioSignals Ltd. based in Oxford, UK, which was originally spun out from Oxford University.

Contact:

OBS Medical
Meredith Formsma
1-866-424-6744
meredith.formsma@obsmedical.com
http://www.obsmedical.com